Table 3. Univariate analysis of PFS and OS.
| Characteristics | N | PFS | OS | |||||
|---|---|---|---|---|---|---|---|---|
| Median (months) | HR (95% CI) | P value | Median (months) | HR (95% CI) | P value | |||
| Age (years) | 1.05 (0.45–2.47) | 0.91 | 0.47 (0.15–1.49) | 0.20 | ||||
| ≤70 | 23 | 5.9 | NE | |||||
| >70 | 17 | 6.2 | 10.6 | |||||
| Sex | 2.40 (0.79–7.29) | 0.12 | 2.69 (0.35–20.99) | 0.35 | ||||
| Male | 32 | 5.7 | 13.7 | |||||
| Female | 8 | 7.3 | 10.6 | |||||
| Performance status | 0.63 (0.27–1.48) | 0.29 | 0.37 (0.11–1.22) | 0.10 | ||||
| 0–1 | 25 | 5.9 | 25.4 | |||||
| 2–3 | 15 | 6.2 | 10.6 | |||||
| Stage | 1.36 (0.31–5.88) | 0.67 | 0.68 (0.08–5.71) | 0.73 | ||||
| ES-SCLC | 36 | 5.9 | 25.4 | |||||
| Recurrent LS-SCLC | 4 | 5.7 | 8.8 | |||||
| Platinum regimen | 1.51 (0.64–3.58) | 0.35 | 0.60 (0.18–1.99) | 0.40 | ||||
| CDDP | 15 | 4.8 | NE | |||||
| CBDCA | 25 | 7.1 | 13.7 | |||||
| Brain metastasis | 0.67 (0.19–2.35) | 0.54 | 1.68 (0.21–13.23) | 0.62 | ||||
| Absent | 35 | 5.9 | 13.7 | |||||
| Present | 5 | 6.2 | NE | |||||
| Liver metastasis | 0.76 (0.27–2.13) | 0.61 | 0.53 (0.14–2.04) | 0.36 | ||||
| Absent | 30 | 5.7 | 25.4 | |||||
| Present | 10 | 6.2 | 10.1 | |||||
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; NE, not evaluable; ES-SCLC, extensive-stage small cell lung cancer; LS-SCLC, limited-stage small cell lung cancer; CDDP, cisplatin; CBDCA, carboplatin.